Alpha Tau Medical(DRTSW)

Focus: Alpha Tau Medical is an Israeli public biotech company founded in 2016 specializing in Diffusing Alpha-emitter Radiation Therapy (DaRT) for solid tumors, with a broad oncology pipeline spanning skin cancer, prostate cancer, pancreatic cancer, and other indications.

Oncology

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Alpha Tau Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Alpha Tau Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

30 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Diffusing Alpha Radiation Emitters Therapy

Liver Metastases

N/A

Clinical Trials (2)

NCT05047094Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

N/A

Help build intelligence for Alpha Tau Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering proprietary technology platform (DaRT seeds) with clinical validation across 20 active trials in high-unmet-need oncology indications
Public company status (DRTSW ticker) provides equity upside potential and operational transparency vs. private biotech
Broad pipeline addressing multiple solid tumors (skin, prostate, pancreatic, breast, lung, glioblastoma) signals sustained development activity and job security

Watch Out For

Zero active job openings reported despite public status suggests limited near-term hiring or organizational scaling constraints
All pipeline programs lack clear phase designation and limited clinical trial density (20 trials total) raises questions about clinical advancement pace and regulatory pathway clarity
Missing financial data (revenue, R&D spend, cash position) and absence of recent news/milestone communication suggests limited market visibility or investor confidence

Generated by Claude from Alpha Tau Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT05829291Alpha Radiation Emitters Device for the Treatment of Liver Metastases (DaRT)

N/A

Radiation: Diffusing Alpha Radiation Emitters Therapy

Prostate Adenocarcinoma

N/A

Clinical Trials (1)

NCT04543903Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer

N/A

DaRT seeds

Carcinoma of the Vulva

N/A

Clinical Trials (1)

NCT06202339Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT).

N/A

Experimental: DaRT seeds

Malignant Tumor

N/A

Clinical Trials (1)

NCT05781555Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors

N/A

DaRT Diffusing Alpha-emitters Radiation Therapy

Vulva Cancer, Recurrent

N/A

Clinical Trials (1)

NCT04761146A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer

N/A

DaRT seeds insertion

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT06026943Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer

N/A

Device: Radiation: Diffusing Alpha Radiation Emitters Therapy

Breast Carcinoma

N/A

Clinical Trials (1)

NCT03970967Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases

N/A

Radiation: Diffusing Alpha Radiation Emitters Therapy

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT06755359Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

N/A

Device :DaRT seeds

Recurrent Glioblastoma

N/A

Clinical Trials (1)

NCT06910306Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

N/A

Radiation: Diffusing Alpha Radiation Emitters Therapy

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT06698458Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

N/A

Radiation: Diffusing Alpha Radiation Emitters Therapy

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT04002479Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

N/A

Radiation: Diffusing Alpha Radiation Emitters Therapy

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT05657743A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer

N/A

Diffusing Alpha-emitter Radiation Therapy

Skin Cancer

N/A

Clinical Trials (1)

NCT04377360Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors

N/A

Radiation: Diffusing Alpha Radiation Emitters Therapy

Skin Cancer

N/A

Clinical Trials (1)

NCT04534127Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

N/A

DaRT seeds

Recurrent Squamous Cell Carcinoma

N/A

Clinical Trials (1)

NCT05323253A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

N/A

Radiation: Diffusing Alpha Radiation Emitters Therapy

Skin Cancer

N/A

Clinical Trials (1)

NCT03737734Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

N/A

Experimental: DaRT seeds

Non-metastatic Prostate Cancer

N/A

Clinical Trials (1)

NCT06202248A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer